Cemeroglu AP, Kocaba CN, Cokun T, Grgey A (2001)
Meikle, P
This means that the drug targets not one, but two unique incretin hormones produced by the human bodywhich has been shown to increase the efficacy of the drug compared to medications that target only GLP-1
From a pharmacokinetic perspective, a half-life of approximately six days means that: Steady-state plasma concentrations are typically reached after approximately four to five half-lives that is, around four to five weeks of once-weekly dosing [1] The drug accumulates gradually in the body during the initial weeks of treatment After discontinuation, meaningful plasma levels may persist for several weeks It is worth noting that pharmacokinetic parameters may vary between individuals due to interindividual differences in body composition, metabolic rate, and other physiological factors
Through these pathways, Epithalon may help support healthier biological aging, better recovery, and improved resilience, though large, modern human trials are still limited